{"id":10233,"date":"2021-02-19T09:30:00","date_gmt":"2021-02-19T08:30:00","guid":{"rendered":"https:\/\/www.emergers.se\/?p=10233"},"modified":"2021-02-19T11:52:28","modified_gmt":"2021-02-19T10:52:28","slug":"simris_d","status":"publish","type":"post","link":"https:\/\/dev.emergers.se\/en\/simris_d\/","title":{"rendered":"New three-pronged focus gives better picture of the potential for Simris"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

SIMRIS ALG<\/span> With mixed performance for the company\u2019s consumer products in the US during 2020, Simris Alg is now broadening its strategic playing field into three clearly defined divisions. With international heavyweight Steven Schapera as chairman, the next step for Biomimetics and Novel Foods will be unlocking the potential of the company\u2019s unique algal platform.  <\/span><\/strong><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n

Report:<\/strong> Johan Widmark | Date:<\/strong> 2021-02-19 <\/span><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

As expected after<\/strong> the company\u2019s sales update earlier in February, which showed a slowdown in the previously rapid US growth, sales of omega-3 in the second half of 2020 were lower than our original expectations. More important, however, was the announcement that cosmetics veteran Steven Shapera is taking over as chairman and that the company is emphasising its future direction with a clearer division into three dedicated business areas.<\/p>

SIMRIS BIOMIMETICS will offer the company\u2019s microalgae for use in advanced skin care and pharmaceuticals through its biotech platform for the discovery and production of various types of active substances. Simris\u2019s research and development platform is offered in combination with its unique production method, which enables the development and manufacture of new and highly active substances and extracts and is therefore expected to command a significantly higher value than other algae products and algae-based ingredients and extracts currently on the market. This also means that the actual value within BIOMIMETICS can be expected to embedded more in the company\u2019s platform for the discovery of new substances than in any individual products or ingredients it can produce.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t
Simris Novel Foods' Alg ganache. Source: Simris Alg<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

The first areas are active enzymes that protect the skin against free radicals, anti-inflammatory and prebiotic polysaccharides, and substances for the treatment of atopic dermatitis. The first products in cosmetic skin care are expected to reach the market in 2022.<\/p>

The BIOMIMETICS business area also includes the company\u2019s investments in the development of production methods for second-generation biopharmaceuticals, which means that the active substance is produced in or extracted from materials of biological origin (i.e. living cells or tissue). The company\u2019s focus in this area is on recombinant DNA technology. In the case of Simris Alg, this means using microalgae as a production platform, which offers advantages compared to \u2018more difficult\u2019 cell lines such as mammalian.<\/p>

SIMRIS NOVEL FOODS focuses on foods and alternative proteins. This is also the origin of the company\u2019s first product line, omega-3 supplements for consumers, which have since been commercialised under the SIMRIS brand and now form the third of the three strategic business areas.<\/p>

The production of omega-3 currently generates two interesting residual products that can be considered the starting point for NOVEL FOODS: firstly, an algal protein powder with over 55% protein content; and secondly, a tasty algal creme. The protein product is already under development for food applications with a multinational company.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

Read more research on Simris Alg here\u00a0<\/span><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

Algal protein as a bulk product has high volume potential, as evidenced by the strong expected growth of 6% CAGR from 2020 to a global market of USD 1 billion by 2026, according to research company Global Market Insights<\/a>, but commands a relatively low price. The relationship in BIOMIMETICS is the opposite, with lower volumes but significantly higher price potential.<\/p>

With our expectations for products in both BIOMIMETICS and NOVEL FOODS to be on the market by 2022, albeit in small volumes, our assessment is that these two divisions have the potential to overshadow the company\u2019s omega-3 products in the long term, although the time horizon is unclear.<\/p>

The distinct separation of BIOMIMETICS and NOVEL FOODS into their own divisions is a major step towards revealing the value and potential of the company\u2019s platform and shifting the focus away from sales volumes for individual products, which should benefit the valuation of Simris Alg.<\/p>

However, it is likely that the company will need to strengthen its finances as early as this year since its cash reserves of SEK 16.5 million will not be enough to cover the annual operating costs of around SEK 20 million. It is therefore reasonable to expect a dilution of 30-50% during the year.<\/p>

All in all, we see Simris Alg as a highly interesting VC case at the forefront of biotechnology, which in the listed environment is unfortunately weighed down by a tunnel vision of the short-term sales growth in its first product arm, omega-3. With the entry of Steven Schapera as chairman and the emphasis on the company\u2019s three strategic business areas, we see both an operational broadening of the business that should contribute to a reversal of sentiment towards the share, and increased chances for the company to attract a new kind of investor who can hopefully see the development more in a VC perspective, with a greater understanding of both the protracted investments and the long-term potential.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

Johan Widmark | Tel: 0739196641 | Mail: johan@emergers.se<\/a><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

DISCLAIMER<\/strong>
Information som tillhandah\u00e5lls p\u00e5 eller via denna webbplats \u00e4r inte avsedd att vara finansiell r\u00e5dgivning. Emergers mottar ers\u00e4ttning f\u00f6r att skriva om bolaget p\u00e5 den h\u00e4r sidan. Bolaget har givits m\u00f6jlighet att p\u00e5verka faktap\u00e5st\u00e5enden f\u00f6re publicering, men prognoser, slutsatser och v\u00e4rderingsresonemang \u00e4r Emergers egna. F\u00f6r att undvika intressekonflikter har Emergers skribenter inga innehav i de noterade bolag vi skriver om. Analysartiklar skall ej betraktas som en rekommendation eller uppmaning att investera i bolagen som det skrivs om. Emergers kan ej garantera att de slutsatser som presenteras i analysen kommer att uppfyllas. Emergers kan ej h\u00e5llas ansvariga f\u00f6r vare sig direkta eller indirekta skador som orsakats av beslut fattade p\u00e5 grundval av information i denna analys. Investerare uppmanas att komplettera med ytterligare material och information samt konsultera en finansiell r\u00e5dgivare inf\u00f6r alla investeringsbeslut. F\u00f6r fullst\u00e4ndiga villkor se here<\/a>.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

SIMRIS ALG Med en blandad utveckling f\u00f6r bolagets konsumentprodukter i USA under 2020 breddar Simris Alg nu sitt strategiska spelf\u00e4lt till tre tydligt definierade inriktningar. Med internationelle tungviktare Schapera som ordf\u00f6rande \u00e4r Biomimetics och Novel Foods n\u00e4sta steg i att l\u00e5sa upp potentialen i bolagets unika algplattform.   Analys: Johan Widmark | Datum: 2021-02-19  SOM …<\/p>\n<\/div>","protected":false},"author":1,"featured_media":10310,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"spay_email":""},"categories":[39],"tags":[43,42],"jetpack_featured_media_url":"https:\/\/dev.emergers.se\/wp-content\/uploads\/2021\/02\/SImris-ro\u0308d-labb.jpg","_links":{"self":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10233"}],"collection":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/comments?post=10233"}],"version-history":[{"count":42,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10233\/revisions"}],"predecessor-version":[{"id":10313,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10233\/revisions\/10313"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/media\/10310"}],"wp:attachment":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/media?parent=10233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/categories?post=10233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/tags?post=10233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}